Novartis

NOVARTIS NEWSROOM (21 press releases)

Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC

PRESS RELEASE -- 11, January 2013

More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression[1] Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by … Read the full press release →

« Previous 1 2